ECP 2026

Date: September 12, 2026 - September 16, 2026
Type: In-person
Location: Europe
Areas of Interest: Oncology

Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. Find us at Booth #501, where we are excited to engage with the pathology community and share how our technology transforms complex data into practical insights.

Stop by our booth to see live demos, meet our team, and discover what's next for SOPHiA DDM™. Check out our full program below.

Industry Satellite Symposia

The SOPHiA GENETICS team will be happy to see you join our co-hosted symposium with AstraZeneca on Monday, 14 September from 07:15 to 08:15 am.

“PTENtion to Detail: From Challenges to Enhanced PTEN Testing”

Speakers:

Lina Li – Product Director, Solid Tumor, SOPHiA GENETICS
Philippe Tanière, MD, Ph.D, CSL – Consultant Histopathologist and Clinical Service Lead, University Hospitals Birmingham NHS Foundation Trust
Slawomir Kubik, Ph.D – Director of Genomic Research, SOPHiA GENETICS

In this session, our speakers will delve into the landscape of PTEN alterations, highlighting its clinical significance in cancer, and discuss how advanced design and bioinformatics can enable more accurate and scalable testing, improving outcomes for patients with PTEN alterations.

Add to Calendar

Poster Presentations

“Understanding complex genomic landscapes of tumors using a novel integrated module for tumor purity, ploidy, and allele specific copy number estimation”

Wednesday, 16 September 2026 | 10:30am - 11:30am | Poster number 008

Add to Calendar

Save the Date

Comments

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Organization(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHiA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services